authors
- Ferrarotto, R
- Wirth, LJ
- Muzaffar, J
- Rodriguez, CP
- Xia, B
- Perez, CA
- Bowles, DW
- Winquist, E
- Hotte, Sebastien
- Metcalf, R
- Even, C
- Gordon, GB
- Gordon, G
- Ho, A
919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- September 2020
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Annals of Oncology Journal
presented at event
- ESMO Virtual Congress Conference